Search results
Results From The WOW.Com Content Network
Bronchopneumonia is a subtype of pneumonia.It is the acute inflammation of the bronchi, accompanied by inflamed patches in the nearby lobules of the lungs. [1]It is often contrasted with lobar pneumonia; but, in clinical practice, the types are difficult to apply, as the patterns usually overlap. [2]
In cases of viral pneumonia where influenza A or B are thought to be causative agents, patients who are seen within 48 hours of symptom onset may benefit from treatment with oseltamivir, or zanamivir, or peramivir. [13] Respiratory syncytial virus (RSV) has no direct acting treatments, but ribavirin is indicated for severe cases. [13]
For children younger than 15 years old, nasopharyngel catheters or nasal prongs are recommended over a face mask or head box. [26] A Cochrane review in 2014 presented a summary to identify children complaining of severe LRTI, however; further research is required to determine the effectiveness of supplemental oxygen and the best delivery method.
"Organizing" refers to unresolved pneumonia (in which the alveolar exudate persists and eventually undergoes fibrosis) in which fibrous tissue forms in the alveoli.The phase of resolution and/or remodeling following bacterial infections is commonly referred to as organizing pneumonia, both clinically and pathologically.
Chlamydia pneumoniae [1] is a species of Chlamydia, an obligate intracellular bacterium [2] that infects humans and is a major cause of pneumonia.It was known as the Taiwan acute respiratory agent (TWAR) from the names of the two original isolates – Taiwan (TW-183) and an acute respiratory isolate designated AR-39. [3]
The AAP Red Book, or Report of the Committee on Infectious Diseases of the American Academy of Pediatrics, is a hardcover, softcover, and electronic reference to the "manifestations, etiology, epidemiology, diagnosis, and treatment of some 200 childhood infectious diseases". The Red Book first appeared as an eight-page booklet in 1938. The most ...
All infants younger than one year who were born at <29 weeks (i.e. ≤28 weeks, 6 days) of gestation are recommended to use palivizumab. Infants younger than one year with bronchopulmonary dysplasia (i.e. who were born at <32 weeks gestation and required supplemental oxygen for the first 28 days after birth) and infants younger than two years with bronchopulmonary dysplasia who require medical ...
It has been sold, as Broncho-Vaxom, in Europe and some South American countries. [1] It is used for children with asthma or recurrent respiratory infections. [1]Studies have shown that OM-85 can enhance both innate and adaptive immunity by promoting the maturation of dendritic cells in the gastrointestinal Peyer's patches, which in turn strengthens immune defenses in the lung mucosa.